scholarly journals Lymphomatous Involvement of Extranodal Site

2020 ◽  
Author(s):  
Keyword(s):  
Extranodal Site ◽  
Lymphomatous Involvement

Value of computed tomography evaluation in the detection of cardio-pericardial lymphomatous involvement

2020 ◽  
Vol 2 (51) ◽  
pp. 7
Author(s):  
Anca Flintoacă-Filip ◽  
Adriana Badea- Selea ◽  
Ioana G. Lupescu
Keyword(s):  
Computed Tomography ◽  
Lymphomatous Involvement

Lymphomatous Involvement of the Skin

Pathology ◽  
1974 ◽  
Vol 6 (1) ◽  
pp. 86
Author(s):  
P. Ironside
Keyword(s):  
Lymphomatous Involvement

scholarly journals Extranodal lymphoma of the head and neck: a pictorial essay

2019 ◽  
Vol 52 (4) ◽  
pp. 268-271
Author(s):  
Pinar Gulmez Cakmak ◽  
Gülsüm Akgün Çağlayan ◽  
Furkan Ufuk
Keyword(s):  
Lymph Nodes ◽  
Head And Neck ◽  
Neck Region ◽  
Extranodal Lymphoma ◽  
Imaging Findings ◽  
Head And Neck Region ◽  
Radiological Features ◽  
Extranodal Site ◽  
Pictorial Essay

Abstract Primary extranodal lymphoma is defined as a lymphoma at a solitary extranodal site, with or without involvement of the lymph nodes. The clinical and radiological features of extranodal lymphoma have been documented in recent studies. In this pictorial essay, we reviewed imaging findings of extranodal lymphoma in the head and neck region.

Unilateral Seizures following Vincristine Intravenous Injection

1984 ◽  
Vol 70 (3) ◽  
pp. 243-244 ◽  
Author(s):  
Francesco Dallera ◽  
Roberto Gamoletti ◽  
Paolo Costa
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Intravenous Injection ◽  
Central Nervous System Toxicity ◽  
Computed Tomographic ◽  
Non Hodgkin Lymphoma ◽  
The Face ◽  
Lymphomatous Involvement ◽  
The Brain ◽  
System Toxicity

A case of acute central nervous system toxicity following the intravenous injection of vincristine was observed in a patient treated with a chemotherapy regimen including cyclophosphamide, doxorubicin and prednisone for non-Hodgkin lymphoma. The neurological symptoms consisted of right-sided epileptiform jacksonian seizures limited to the face, that lasted about 10 min, followed by spontaneous recovery. A cerebrospinal fluid study and computed tomographic scan of the brain failed to reveal any central nervous system lymphomatous involvement.

Anatomic definition of a vulnerable extranodal site in AV node reentry

1994 ◽  
Vol 57 (5) ◽  
pp. 1273-1280 ◽  
Author(s):  
William L. Holman ◽  
Peter G. Anderson ◽  
Russell D. Spruell ◽  
Albert D. Pacifico
Keyword(s):  
Av Node ◽  
Extranodal Site ◽  
Definition Of

Non-Hodgkin's Lymphoma Primarily Involving the Bronchial Tree

1987 ◽  
Vol 73 (6) ◽  
pp. 593-599 ◽  
Author(s):  
Paolo Verdiani ◽  
Stefania Di Carlo ◽  
Vincenzo Sforza ◽  
Rosa Santopietro
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Bronchial Tree ◽  
Small Cell ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Chest X Ray ◽  
Lymphomatous Involvement ◽  
Small Cell Bronchogenic Carcinoma ◽  
Centroblastic Lymphoma

Among extranodal localizations, the bronchial one is very unusual, especially as primary involvement. The authors present 2 cases of non-Hodgkin's lymphoma (NHL) admitted to the hospital because of thoracic abnormalities. Chest x-ray revealed lobar atelectasis. Fiberoptic bronchoscopic findings agreed with the diagnosis of unresectable bronchogenic tumor in both cases. Histologic examination of biopsy specimens was nonrevealing in the first patient, and suggested small cell lung cancer in the second one. Further histologic and immunohistochemical examinations excluded bronchial tumors (particularly small cell bronchogenic carcinoma) and led to the diagnosis of lymphocytic lymphoma in one case and centroblastic lymphoma in the other. In the differential diagnosis of bronchogenic tumors, it is necessary to keep in mind the hypothesis of lymphomatous involvement of the bronchial wall, although it rarely occurs.

Evaluation of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Non-Hodgkin’s Lymphoma (NHL) Having Previously Received Autologous Stem Cell Transplant (ASCT).

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 5238-5238 ◽  
Author(s):  
Samuel A. Jacobs ◽  
Barry McCook ◽  
Frank Torok ◽  
Norbert Avril ◽  
Nick Vidnovic ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Platelet Count ◽  
B Cell ◽  
Cell Lymphoma ◽  
Prior History ◽  
Ibritumomab Tiuxetan ◽  
Heavily Pretreated ◽  
History Of ◽  
Lymphomatous Involvement ◽  
Yttrium 90

Abstract Background: As the first radioimmunotherapeutic (RIT) agent approved for the treatment of relapsed or refractory B-cell NHL, yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) has been shown to achieve durable responses in heavily pretreated NHL patients. In phase 1–2, the eligibility criteria for 90Y ibritumomab tiuxetan therapy excluded patients with hypocellular bone marrow (<15%), lymphomatous involvement >25%, or prior ASCT due to concern of depleting the bone marrow reserve. However, Kaminski et al previously demonstrated that a parallel RIT agent, 131I tositumomab, was safe and efficacious when administered after ASCT (Blood2000; 96:1259–66). We report our experience of using ibritumomab tiuxetan in NHL patients with a prior history of ASCT. Methods: Patients with histologically confirmed relapsed or refractory B-cell NHL, ≥18 years, platelet counts >100,000/mm3, bone marrow cellularity >15%, and lymphomatous involvement <25% were eligible for treatment. In a series of 40 patients treated with ibritumomab tiuxetan at the UPMC Cancer Center, 6 patients with prior ASCT were treated. A standard course of ibritumomab tiuxetan was given, with the therapeutic dose of 90Y ibritumomab tiuxetan administered at 0.3 mCi/kg (the initial patient, and another with platelet count ≥150,000/mm3) or the standard dose of 0.4 mCi/kg 90Y in the 4 remaining cases (baseline platelet count >150,000/mm3). Pretreatment diagnostic PET/CT scans were taken for all patients and evaluated for areas of lymphomatous involvement. Follow-up scans were performed approximately 12 weeks after treatment to assess patient response. Maximum toxicities were monitored weekly over a 12-week period after therapy and classified according to CTCAE v. 3.0 toxicity criteria. Results: Patients with a prior history of ASCT had received a minimum of 4 previous regimens (range, 4–7). Subjects presented with follicular NHL (n = 3), transformed NHL (n = 1), large cell lymphoma (n = 1), and mantle cell lymphoma (n = 1). Six patients were evaluable for toxicity and 5 patients were evaluable for response. Observed toxicities were consistent with those expected in this patient population, with 33% (2/6) and 17% (1/6) of patients experiencing grade 4 thrombocytopenia and grade 3 neutropenia, respectively. Episodes of bleeding or neutropenic fever were not observed. Of the 5 patients evaluable for response, 1 patient with follicular lymphoma had a complete response to ibritumomab tiuxetan as determined by FDG-PET imaging. Conclusions: Ibritumomab tiuxetan therapy is feasible and safe in NHL patients who have previously received ASCT. Heavily pretreated patients can benefit from the administration of ibritumomab tiuxetan although additional data are needed to further characterize the degree of clinical response after ASCT.

The Relevance of Increased Tonsil Uptake When Restaging Lymphoma with Positron Emission Tomography

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3133-3133
Author(s):  
Javier Munoz ◽  
Belisario Arango ◽  
Jessica Schering ◽  
James Morrison ◽  
Ishani Dalal ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Conflicts Of Interest ◽  
Standardized Uptake Value ◽  
Emission Tomography ◽  
Invasive Approach ◽  
Fdg Uptake ◽  
Tonsillar Tissue ◽  
Positron Emission ◽  
Lymphomatous Involvement ◽  
The Mean

Abstract Abstract 3133 Introduction: Significant tonsil uptake is sometimes observed in F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) after treatment. Some patients undergo tonsillectomy or FNA (fine needle aspiration) to rule out malignant involvement particularly when management depends on restaging (Figure 1). Our study describes the incidence and degree of tonsil FDG uptake in a large group of lymphoma patients that underwent PET scanning. Patients and Methods: Single institution, retrospective chart review by ICD code, 617 lymphoma patients that underwent PET at our institution from 2004 to 2009. Results of PET were compared to pathological diagnosis of tonsillectomy (Table 1) or FNA biopsy (Table 2) when available which was performed at physician's discretion. Patients that were diagnosed with lymphoma during restaging studies performed for a different primary malignancy were excluded. Results and Discussion: All 8 tonsillectomies and FNA biopsies performed after a restaging PET that showed increased tonsil uptake were negative for malignancy (Figure 2). All of these 8 patients had an initial previous PET that did not show increased tonsil uptake and also these 8 patients remained in remission from their lymphoma after the procedure was performed. In contrast, 6 out of 7 patients that underwent tonsillectomy or FNA at diagnosis were positive for malignancy (Table 3). Differences among tonsil FDG uptake has been thought to reflect differences in activity of “physiological” inflammation of the palatine tonsils. Increased glucose metabolism during active inflammation in the case of chronic tonsillitis or lymphocyte proliferation in the case of a patient that has received prior chemotherapy (likely experiencing compensatory extra medullar lymphoid hyperplasia) were thought to be causes of high FDG uptake in the tonsils. The significance of such increased tonsil FDG uptake is currently unknown however previous studies suggest that normal pharyngeal palatine tonsil uptake was generally symmetrical and that the difference in maximal standardized uptake value (SUVmax) between right and left tonsils (right-to-left ratio or a surrogate of symmetry) in the same patient might be helpful in detecting malignant tissue. The mean right-to-left ratio of tonsillar SUV was 4.55 in patients with confirmed malignant pathology and 1.53 in patients with documented benign tonsillar tissue (Table 4). The mean tonsillar SUVmax was 15.35 in patients with confirmed malignant pathology and 7.05 in patients with documented benign tonsillar tissue hence SUVmax seems to be useful in differentiating tumor from physiological accumulation. Younger patients with low SUV max symmetric tonsillar uptake and no other abnormal FDG areas seen during restaging PET could probably be watched non-invasively. Conclusions: At the time of initial staging PET, increased tonsil uptake showed true lymphomatous involvement in most cases. At restaging, increased tonsil uptake displayed no cases positive for lymphomatous involvement as all tonsillectomies and FNA biopsies were negative for malignancy. These findings seem to be valid irrespective of the subtype of lymphoma. Our study supports a conservative non-invasive approach because physiologic uptake is the most common cause of increased tonsil uptake when restaging lymphoma patients after treatment has been completed. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document